Medicare Enrolled
Dr. Jonathan Pourmorady
Gastroenterology · Los Angeles, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pourmorady from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pourmorady?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pourmorady
Dr. Jonathan Pourmorady is a gastroenterology specialist in Los Angeles, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Pourmorady performed 2,495 Medicare services across 997 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pourmorady received a total of $4,619 from 33 pharmaceutical and/or device companies across 234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pourmorady is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 6% volume in CA
$4,619 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,495
Medicare services
Top 6% in CA for gastroenterology
997
Unique beneficiaries
$86
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~208 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,453 | $66 | $450 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
240 | $103 | $255 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
192 | $145 | $800 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
139 | $76 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
106 | $135 | $510 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
84 | $65 | $2,250 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
58 | $98 | $550 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
54 | $93 | $2,950 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
38 | $206 | $2,782 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
27 | $145 | $2,200 |
| New patient office visit, complex (60-74 min) | 26 | $144 | $624 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
22 | $105 | $500 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $76 | $401 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
15 | $123 | $375 |
| Endoscopic control of upper GI bleeding A flexible endoscope is used to locate and stop bleeding in the esophagus, stomach, or upper small intestine. |
14 | $161 | $1,835 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
12 | $85 | $3,500 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,619
Total received (2019-2024)
Avg $770/year across 6 years
Top 32% in CA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
234
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,619 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,547
2023
$1,444
2022
$763
2021
$427
2020
$348
2019
$90
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$354
Takeda Pharmaceuticals U.S.A., Inc.
$301
ABBVIE INC.
$151
Regeneron Healthcare Solutions, Inc.
$126
Merck Sharp & Dohme LLC
$98
Novartis Pharmaceuticals Corporation
$78
QOL Medical, LLC
$78
AIMMUNE THERAPEUTICS, INC.
$58
Phathom Pharmaceuticals, Inc.
$48
Alnylam Pharmaceuticals Inc.
$44
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$35
Neurelis, Inc.
$29
Gilead Sciences, Inc.
$27
Braintree Laboratories, Inc.
$25
GENZYME CORPORATION
$25
Lilly USA, LLC
$24
Kiniksa Pharmaceuticals International, plc
$24
IRONWOOD PHARMACEUTICALS, INC
$23
Top 3 companies account for 52.1% of 2024 payments
All-time payments by company (2019-2024) ›
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$951
ABBVIE INC.
$669
Takeda Pharmaceuticals U.S.A., Inc.
$585
Janssen Biotech, Inc.
$557
QOL Medical, LLC
$197
Regeneron Healthcare Solutions, Inc.
$174
NESTLE HEALTHCARE NUTRITION INC.
$172
Merck Sharp & Dohme LLC
$171
GENZYME CORPORATION
$116
Braintree Laboratories, Inc.
$78
Novartis Pharmaceuticals Corporation
$78
Gilead Sciences, Inc.
$71
Daiichi Sankyo Inc.
$71
Alnylam Pharmaceuticals Inc.
$70
Celgene Corporation
$67
AIMMUNE THERAPEUTICS, INC.
$58
RedHill Biopharma Inc.
$58
Lilly USA, LLC
$53
Phathom Pharmaceuticals, Inc.
$48
PFIZER INC.
$48
Ironwood Pharmaceuticals, Inc
$47
INTERCEPT PHARMACEUTICALS, INC.
$35
Almatica Pharma LLC
$33
AbbVie Inc.
$32
Neurelis, Inc.
$29
Kiniksa Pharmaceuticals International, plc
$24
IRONWOOD PHARMACEUTICALS, INC
$23
Janssen Pharmaceuticals, Inc
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
IDORSIA PHARMACEUTICALS US INC
$18
Nestle HealthCare Nutrition Inc.
$17
Merck Sharp & Dohme Corporation
$17
Bausch Health US, LLC
$12
Top 3 companies account for 47.7% of all-time payments
Associated products mentioned in payments ›
AMVUTTRA · Arcalyst · COLOGUARD · DIFICID · DUPIXENT · ENTRESTO · ENTYVIO · GIVLAARI · HUMIRA · INJECTAFER · JARDIANCE · LEQVIO · LINZESS · LOREEV XR · Linzess · MOTEGRITY · OCALIVA · PRALUENT · QUVIVIQ · RINVOQ · SKYRIZI · SPIRIVA · STEGLATRO · STELARA · SUCRAID · SUFLAVE · SUPREP BOWEL PREP · Sucraid · TREMFYA · TRINTELLIX · TRULANCE · TRULICITY · Talicia · VALTOCO · VIBERZI · VOQUEZNA · WELLBUTRIN · XARELTO · XELJANZ · XIFAXAN · ZENPEP · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Gastroenterologists within 10 mi
475
Per 100K population
4.8
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pourmorady is a clinical cardiology specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pourmorady experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Pourmorady performed 1,453 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pourmorady receive payments from pharmaceutical companies?
Yes. Dr. Pourmorady received a total of $4,619 from 33 companies across 234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pourmorady's costs compare to other gastroenterologists in Los Angeles?
Dr. Pourmorady's average Medicare payment per service is $86. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pourmorady) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Los Angeles
Browse gastroenterologists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in CA
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in CA
Which CA gastroenterologists receive the most from drug and device companies.
By company
Salix Pharmaceuticals, a division of Bausch Health US, LLC Payments to Doctors
See all physicians who received payments from Salix Pharmaceuticals, a division of Bausch Health US, LLC.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology